Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

Trial Profile

A Phase I Study of Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas

Suspended
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs LMP 744 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Dec 2018 Status changed from recruiting to suspended as Sponsor halted accrual due to low drug supply.
    • 27 Nov 2018 Planned primary completion date changed from 1 Dec 2018 to 2 Oct 2020.
    • 27 Nov 2018 Planned End Date changed from 2 Oct 2019 to 2 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top